Inventor · disambiguated record
Paul Rennert
Also filed as: RENNERT PAUL · RENNERT PAUL D · RENNERT PAUL DAVID
33 granted patents·23 pending applications·8,902 citations·filing 1994–2021
98Inventor score
Top patents by PatentIndex Score
56 records- 0199US7232566B2Methods for treating HIV infected subjectsGENETICS INST LLC·Filed 2005·Granted Jun 19, 2007·814 cites·64 claims
- 0299US7175843B2Methods for selectively stimulating proliferation of T cellsUS NAVY·Filed 2006·Granted Feb 13, 2007·821 cites·65 claims
- 0399US7144575B2Methods for selectively stimulating proliferation of T cellsUS NAVY·Filed 2003·Granted Dec 5, 2006·799 cites·24 claims
- 0499US6905681B1Methods for selectively stimulating proliferation of T cellsINST GENETICS LLC·Filed 1999·Granted Jun 14, 2005·913 cites·18 claims
- 0599US6905680B2Methods of treating HIV infected subjectsUS NAVY·Filed 1996·Granted Jun 14, 2005·879 cites·14 claims
- 0699US6887466B2Methods for selectively stimulating proliferation of T cellsUS NAVY·Filed 1999·Granted May 3, 2005·914 cites·19 claims
- 0799US6534055B1Methods for selectively stimulating proliferation of T cellsGENETICS INST·Filed 1995·Granted Mar 18, 2003·1k cites·29 claims
- 0899US6352694B1Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cellsGENETICS INST·Filed 1995·Granted Mar 5, 2002·1.2k cites·32 claims
- 0999US5858358AMethods for selectively stimulating proliferation of T cellsUS NAVY·Filed 1994·Granted Jan 12, 1999·885 cites·33 claims
- 1097US7479269B2Methods for selectively enriching TH1 and TH2 cellsGENETICS INST LLC·Filed 2006·Granted Jan 20, 2009·32 cites·12 claims
- 1195US6875846B2Heterologous polypeptide of the TNF familyBIOGEN IDEC INC·Filed 2002·Granted Apr 5, 2005·95 cites·16 claims
- 1294US10508143B1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2016·Granted Dec 17, 2019·7 cites·4 claims
- 1394US6719972B1Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodiesREPLIGEN CORP·Filed 1994·Granted Apr 13, 2004·126 cites·11 claims
- 1494US6444792B1CTLA4-Cγ4 fusion proteinsREPLIGEN CORP·Filed 1999·Granted Sep 3, 2002·194 cites·1 claims
- 1593US7579001B2Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disordersBIOGEN IDEC INC·Filed 2006·Granted Aug 25, 2009·17 cites·19 claims
- 1693US7169387B2Antagonists of tweak and of tweak receptor and their use to treat immunological disordersBIOGEN IDEC INC·Filed 2004·Granted Jan 30, 2007·37 cites·18 claims
- 1792US6750334B1CTLA4-immunoglobulin fusion proteins having modified effector functions and uses thereforREPLIGEN CORP·Filed 1996·Granted Jun 15, 2004·104 cites·4 claims
- 1890US10066023B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2016·Granted Sep 4, 2018·3 cites·16 claims
- 1988US10669349B2Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2017·Granted Jun 2, 2020·2 cites·12 claims
- 2085US10072094B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2017·Granted Sep 11, 2018·2 cites·28 claims
- 2184US11059904B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2018·Granted Jul 13, 2021·1 cites·29 claims
- 2283US8440189B2Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disordersRENNERT PAUL·Filed 2011·Granted May 14, 2013·5 cites·13 claims
- 2383US7309492B2Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosusBIOGEN IDEC INC·Filed 2001·Granted Dec 18, 2007·13 cites·7 claims
- 2482US7276241B2Methods of treating a tumor that expresses APRIL by administering BCMAAPOXIS SA·Filed 2002·Granted Oct 2, 2007·25 cites·24 claims
- 2581US7744891B2Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseasesBIOGEN IDEC INC·Filed 2007·Granted Jun 29, 2010·3 cites·35 claims
- 2672US7597887B2KIM-1 antagonists and use to modulate immune systemBIOGEN IDEC INC·Filed 2003·Granted Oct 6, 2009·4 cites·4 claims
- 2772US7255854B1Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseasesBIOGEN INC·Filed 1999·Granted Aug 14, 2007·21 cites·35 claims
- 2870US2009155836A1Methods for treating hiv infected subjectsUNIV MICHIGAN·Filed 2008·Application pending·0 cites
- 2969US11807691B2Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·0 cites·15 claims
- 3068US2010061985A1Antagonists of tweak and of tweak receptor and their use to treat immunological disordersBIOGEN IDEC INC·Filed 2009·Application pending·0 cites
- 3167US2006205069A1Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cellsGENETICS INST LLC·Filed 2006·Application pending·0 cites
- 3267US2022313720A1Targeted cancer therapyUS HEALTH·Filed 2021·Application pending·0 cites
- 3366US7592007B2Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodiesDANA FARBER CANCER INST INC·Filed 2003·Granted Sep 22, 2009·2 cites·4 claims
- 3464US2005196402A1CTLA4-Cy4 fusion proteinsREPLIGEN CORP·Filed 2004·Application pending·0 cites
- 3561US11207339B2Targeted cancer therapyUS HEALTH·Filed 2016·Granted Dec 28, 2021·0 cites·17 claims
- 3661US2010080798A1Kim-1 antagonists and use to modulate immune systemBIOGEN IDEC INC·Filed 2009·Application pending·0 cites
- 3761US2004151725A1CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses thereforFiled 2004·Application pending·0 cites
- 3856US2015218247A1Taci as an anti-tumor agentBIOGEN IDEC INC·Filed 2015·Application pending·0 cites
- 3955US2023220095A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4055US2004013674A1Taci as an anti-tumor agentFiled 2001·Application pending·0 cites
- 4155US2022112292A1Single domain antibodies against cll-1ALETA BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4254US8287874B2Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseasesBROWNING JEFFREY L·Filed 2010·Granted Oct 16, 2012·0 cites·29 claims
- 4352US2002015703A1Antagonists of tweak and of tweak receptor and their use to treat immunological disordersFiled 2001·Application pending·0 cites
- 4450US2022387487A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4549US8206705B2KIM-1 antibodies for treatment of TH2-mediated conditionsRENNERT PAUL·Filed 2006·Granted Jun 26, 2012·0 cites·37 claims
- 4649US2002114814A1CTLA4-Cgamma4 fusion proteinsFiled 2001·Application pending·0 cites
- 4749US2005124543A1Heterologous polypeptide of the TNF familyFiled 2005·Application pending·0 cites
- 4848US11891426B2CD19 variantsALETA BIOTHERAPEUTICS INC·Filed 2018·Granted Feb 6, 2024·0 cites·10 claims
- 4948US2020306375A1Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5048US2021130494A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →